Pipeline

Metavac® RSV-HMPV Preclinical PoC executed – Start Phase I in Q3 2025
Live-attenuated vaccine candidate
Produced on GMP grade Vero cell line
Administration: Intranasal
Target market: >$5bn
crossmenu